Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Cash & Current Investments (2019 - 2025)

Silence Therapeutics' Cash & Current Investments history spans 6 years, with the latest figure at $158.9 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 14.58% year-over-year to $158.9 million; the TTM value through Dec 2025 reached $158.9 million, down 14.58%, while the annual FY2025 figure was $158.9 million, 14.58% down from the prior year.
  • Cash & Current Investments for Q4 2025 was $158.9 million at Silence Therapeutics, up from $102.2 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $186.1 million in Q4 2024 and bottomed at $49.2 million in Q4 2022.
  • The 4-year median for Cash & Current Investments is $114.2 million (2025), against an average of $120.9 million.
  • The largest annual shift saw Cash & Current Investments skyrocketed 159.4% in 2021 before it plummeted 50.32% in 2022.
  • A 4-year view of Cash & Current Investments shows it stood at $99.1 million in 2021, then tumbled by 50.32% to $49.2 million in 2022, then surged by 277.83% to $186.1 million in 2024, then dropped by 14.58% to $158.9 million in 2025.
  • Per Business Quant, the three most recent readings for SLN's Cash & Current Investments are $158.9 million (Q4 2025), $102.2 million (Q3 2025), and $114.2 million (Q2 2025).